|| List of recent Vascular-related patents
|Vascular flow assessment|
A method for vascular assessment is disclosed. The method comprises receiving a plurality of 2d angiographic images of a portion of a vasculature of a subject, and processing the images to produce a stenotic model over the vasculature, the stenotic model having measurements of the vasculature at one or more locations along vessels of the vasculature.
|Radiopaque markers for visualizing an edge of an endovascular graft|
An endovascular prosthesis is disclosed that includes a tubular graft and a radiopaque marker attached to envelop or enfold an edge of the tubular graft. A first segment of the radiopaque marker extends against an interior surface of the tubular graft and a second segment of the radiopaque marker extends against an exterior surface of the tubular graft such that the first and second segments sandwich or straddle the edge of the tubular graft.
|Intravascular cardiac restraining implants and methods for treating heart failure|
Intravascular cardiac restraining implants designed for treatment of heart disease and heart failure and methods for their use. The disclosed implants can be used to reshape or reinforce a diseased, weakened or distended portion of a patient's heart to counteract heart disease and heart damage.
|Drug-delivery endovascular stent and method of forming the same|
An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition.
|Material structures for intravascular device|
An intravascular device for keeping open a previously constricted site within a vessel and for minimizing tissue debris at such a site from closing off the vessel is provided. The device includes an expandable substantially tubular body having a distal end and a proximal end.
|Emergency vascular repair prosthesis deployment system|
A deployment device for repair of a transected body vessel is described herein. Device can have a handle and one or more shafts coupled thereto.
|Vascular closure system toggle placement|
Methods of controlling the orientation of a toggle of a puncture sealing device are disclosed. In one example, a proximal end of a toggle of the sealing device can be trapped between a release tube and a delivery tube while the puncture sealing device is being moved into a vessel through a puncture site of the vessel.
|Clot retrieval device for removing occlusive clot from a blood vessel|
A clot retrieval device (9501) for removing occlusive clot from a blood vessel comprises an inner elongate body (9503) and an outer elongate body (9504) at least partially overlying the inner elongate body (9503). The device also comprises an elongate member or shaft (9502) having a proximal end which extends exterior of a patient so that a user can retrieve the stent-basket device and captured clot by retracting the shaft (9502).
|Renal nerve ablation catheter|
Medical devices for ablating nerves perivascularly and methods for making and using the same are disclosed. An example medical device may include an expandable frame slidably disposed within a catheter shaft.
|Methods for counteracting rebounding effects during solid state resistance welding of dissimilar materials|
The present disclosure is directed to methods for joining initially separate members of different metallic materials, e.g., as in joining segments of a multi-segment intravascular guide wire, as well as multi-segment intravascular guide wires so formed. Initially separate members are provided, which members comprise different metallic materials relative to one another (e.g., stainless steel and nitinol).
|Second generation fatty acid compositions, formulations, and methods of use and synthesis thereof|
An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5z,8z,11z,14z,17z-eicosapentaenoic ethanolamide (epa ethanolamide), 4z,7z,10z,13z,16z,19z-docosahexaenoic ethanolamide (dha ethanolamide), and at least one tocotrienol.
|Rnai-mediated inhibition of select receptor tyrosine kinases for treatment of pathologic ocular neovascularization-related conditions|
Rna interference is provided for inhibiton of expression of select receptor tyrosine kinase (rtk) targets in ocular neovascularization-related conditions, including those cellular changes resulting from the signal transduction activity of the select rtk targets that lead directly or indirectly to ocular nv, abnormal angiogenesis, retinal vascular permeability, retinal edema, diabetic retinopathy particularly proliferative diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, sequela associated with retinal ischemia, and posterior segment neovascularization.. .
|Adjuvant chemotherapy for anaplastic gliomas|
The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-pbn) in the treatment and prevention of gliomas. The 2,4-ds-pbn may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization..
|Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases|
The present methods and compositions are of use for treatment of conditions involving fibrosis, such as peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a pde-4 inhibitor, a pde-5 inhibitor, a compound that elevates cgmp and/or pkg, a stimulator of guanylyl cyclase and/or pkg, a combination of a compound that elevates cgmp, pkg or no with an antioxidant that decreases ros, or a compound that increases mmp activity..
|Combinations of corroles and statins|
Embodiments of the invention relate to methods of treatment a cardiovascular disease in a patient comprising administering an effective amount of a statin or a pharmaceutically acceptable salt thereof in combination with an effective amount of a transition metal complex of a corrole, an optically active isomer thereof or a pharmaceutically acceptable salt thereof. Further embodiments refer to pharmaceutical compositions comprising a statin and a corrole..
|Antagonists of cb1 receptor|
The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .
|Peptide bfp4 for promoting osteogenesis or vascularization and use thereof|
Disclosed are a peptide for promoting osteogenesis and vascularization, and the use thereof. The peptide has a low molecular weight so that it can be economically produced.
|Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport|
The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient.
|Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia|
The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably alzheimer's disease or vascular dementia.. .
|Methods of treating complications and disorders associated with g-csf administration|
The present embodiments relate to novel uses of mpo inhibitors and inhibitors of mpo and e-selectin binding. In some embodiments, methods are provided for treating g-csf-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits e-selectin receptor/ligand interaction or inhibits mpo activity.
|Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2/kdr)|
Phage displayed recombinant antibody library was developed and the library was screened against vegfr-2. After screening and elisa experiments two recombinant antibodies showing binding properties to vegfr-2 was obtained.
|Method of reducing multi-drug resistance using inositol tripyrophosphate|
Inositol trisphosphate (itpp) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. Itpp also treats, alone or in combination, multi-drug resistant cancers.
|Sac liner for aneurysm repair|
Systems and methods for managing aneurysms provide additional support to an aneurysmal wall by disposing a flexible vascular liner against or in close proximity to the aneurysmal wall. The liner is flexibly expansive to conform to the wall of the aneurysm.
|Gate wire for contralateral leg access|
An endovascular delivery system includes a pre-loaded, small guide wire for snaring via the contralateral side of a bifurcated prosthesis for deployment of a graft extension to the contralateral side of the bifurcated prosthesis. The pre-loaded guidewire avoids a cannulation step in the deployment of typical bifurcated stent grafts.
|Controlled deployable medical device and method of making the same|
Controlled deployable medical devices that are retained inside a body passage and in one particular application to vascular devices used in repairing arterial dilations, e.g., aneurysms. Such devices can be adjusted during deployment, thereby allowing at least one of a longitudinal or radial re-positioning, resulting in precise alignment of the device to an implant target site..
|Method and system for closing a vascular hole|
Various embodiments of methods for closing vascular holes and associated vascular closure devices are described herein. The methods, generally speaking, use hemostatic devices intended to stop bleeding by closing vascular access puncture sites following percutaneous diagnostic or therapeutic procedures.
|Vascular closure device with improved side loading|
A tissue puncture closure device includes a vessel locator and a sealing plug delivery member. The vessel locator includes an expandable member.
|Device for delivery of medical devices to a cardiac valve|
A catheter device is disclosed for transvascular delivery of a medical device to a cardiac valve region of a patient. The catheter device comprises an elongate sheath (2) with releasable locking members for controllably locking the elongate sheath in a shape at least partly along its length from a relaxed state to a locked state when positioned in relation to a cardiac valve.
|Connection of an endovascular intervention device to a manipulation member|
A device for intravascular intervention can comprise an intervention element, an elongate manipulation member, and a joining element. The elongate member can comprise a hooked portion extending about a proximal portion of the intervention element.
|Connection of a manipulation member, including a bend without substantial surface cracks, to an endovascular intervention device|
A device for intravascular intervention can comprise an intervention element, an elongate manipulation member, and a joining element. The elongate element can comprise a hooked portion extending about a proximal portion of the intervention element.
|Vessel shaping devices and methods|
Disclosed is a medical device for shaping a vessel accommodated therein in a predetermined form, wherein said vessel includes a vein and an artery which are connected at a artifactual vascular junction thereof. The device includes an external vascular support (100) having at least one vascular support wall for accommodating an exterior vessel wall of a vessel therein when implanted.
|Systems and methods for attaching a prosthesis within a body lumen or hollow organ|
Systems and methods introduce and deploy prosthesis into a blood vessel or hollow body organ by intra-vascular access. The prosthesis is secured in place by fasteners which are implanted by an applier that is also deployed by intra-vascular access.
|Apparatus and method for treating cardiovascular diseases|
A removable apparatus is provided for temporary implantation in a pulmonary vein for ablating atrial tissue surrounding the antrum of the pulmonary vein to treat atrial fibrillation in a subject. The apparatus comprises an electrically-insulated expandable support member and a retrieval mechanism.
|Circulatory dynamics measurement apparatus|
The circulatory dynamics measurement apparatus comprises: a blood pressure-computing unit, which calculates the maximum blood pressure value (sys); a vascular sclerosis-computing unit, which calculates the vascular sclerosis index (vsi); and a display unit for displaying a graph having a horizontal axis that represents the maximum blood pressure and a vertical axis that represents the vascular sclerosis index. The display unit displays the position determined by the calculated maximum blood pressure value and the calculated vascular sclerosis index in the plotting area of the graph..
|Apparatus and method for non-invasive measurement of cardiac output|
A comparatively light and compact permanent magnet arrangement for an mri apparatus has a pair of opposed permanent magnet arrays with a shimming system to adjust the uniformity and strength of a magnetic field in a central chamber of the apparatus. The mri apparatus is used to examine the extremities of a patient to determine cardiovascular characteristics from an analysis of the blood flow through selected arteries in the extremity.
|Method and apparatus for obtaining cardiovascular information by measuring between two extremities|
A method and an apparatus for obtaining information on a cardiovascular system beat by beat and continuously which are based exclusively on measurements between two limbs and effected with a pair of distal electrodes on each limb. The measurement is made by causing an alternating current to flow between one electrode of each limb and measuring the potential difference between the other two electrodes, one also on each limb.
|Biocompatible and biodegradable elastomer|
The present invention provides a biocompatible and biodegradable elastomer, comprising a hard segment and a soft segment. The hard segment is formed by reacting diisocyanate and a chain extender; and the soft segment is comprising a biodegradable oligomer diol, wherein the biodegradable oligomer diol is selected from the group consisting of polycaprolactone diol, polyethylene butylene adipate diol (peba diol), poly-l-lactic acid diol (plla diol), polylactic acid diol and any combination thereof.
|Rapamycin formulations and methods of their use|
Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet amd and dry amd, and preventing transition of dry amd to wet amd, using the liquid rapamycin formulations described herein..
Wherein a1, a2, a3 and r1 to r8 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with hdl-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.. .
|Thiolactams and uses thereof|
Wherein r1, r2, r3, r4, r5, and r6 are as described in the specification. The compounds are inhibitors of plk and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders..
|Peptide-based peroxidase inhibitors and methods of using same|
The present invention provides peptide-based peroxidase inhibitors having the formula aa1-aa2-aa3, wherein aa1 is a positively charged, negatively charged or neutral amino acid, aa2 is a redox active amino acid, and aa3 is an amino acid possessing a reducing potential such that aa3 is capable of undergoing a redox reaction with a radical of amino acid aa2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury.